54th ESPGHAN
Noventure will be present at the 54th ESPGHAN, that will take place in Copenhaguen, Denmark 22-25 June 2022
TASECTAN®
0
Launch of TASECTAN® AF in Denmark
Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April.
Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children.
“Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”
Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann Pediatr Child Health 2020; 8(6): 1194.
We are proud to announce the publication “Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”. This article elaborates on how a friendlier use of ORS is possible by improving palatability and texture, as well as limiting the volume per dosing. As a result, treatment compliance and, subsequently, therapeutic success, are more likely than with standard ORS preparations.
